Please login to the form below

Not currently logged in
Email:
Password:

Leo Pharma’s Enstilar approved by FDA

Topical psoriasistreatment given the green light
FDA

The FDA has approved Leo Pharma's Enstilar foam for the treatment of plaque psoriasis.

The approval comes on the back of a clinical trial that showed patients achieved significant degrees of improvement after only two weeks of use.

In the phase III trial, over half of patients treated with Enstillar were 'clear' or 'almost clear' by week four as assessed by the investigator global assessment (IGA) score of disease severity. Additionally, more than half of patients treated with Enstillar achieved a 75% improvement in psoriasis and severity index (PASI).

Barbara Osborne, president and CEO of Leo Pharma, said: “The approval of Enstillar may offer the appropriate plaque psoriasis patients a new treatment option in an elegant vehicle that provides rapid relief from symptoms.

“We are excited about the approval of Enstillar as it represents another step in Leo Pharma's unwavering commitment to helping patients living with this chronic, often debilitating disease.”

Enstilar (calcipotriene/betamethasone dipropionate) is a once-daily, alcohol free foam formulation in a pressurised can that allows application across large areas of the body.

Adverse reactions were reported in less than 1% of patients and included skin irritation, folliculitis and exacerbation of psoriasis.

The new approval means that Enstilar will now compete with other oral drugs for psoriasis such as Celgene's Otezla (apremilast) as well as Pfizer's Enbrel (etanercept), which is coming under competition from numerous biosimilars.

Additionally, newer entrants like Lilly's ixekizumab and Novartis' Consentyx (sekucinumab) are expected to further drive growth of the global psoriasis market from $6bn in 2012 to nearly $9bn by 2023. 

Article by
Nikhil Patel

21st October 2015

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics